Xspray Pharma

Declaration of Voting Results & Voting Rights Announcements • Oct 31, 2022

Number of shares and votes in Xspray Pharma

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the number of shares and votes in Xspray Pharma AB has changed as a result of shares being registered due to the directed share issue which was carried out in October 2022.

Through the direct share issue, carried out in October 2022, the number of outstanding shares and votes has increased by 2,000,000, from 20,680,408 to 22,680,408. The share capital has increased by SEK 2,000,000, from SEK 20,680,408 to SEK 22,680,408.

For further information, please contact:

Christina Malmberg Hägerstrand Senior Vice President Communications & Investor Relations Xspray Pharma AB Mob: +46 (0) 72 855 93 29 E-mail: christina.malmberg.hagerstrand@xspray.com

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development. Xspray Pharma uses its innovative, patented RightSize™ technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.

The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today's original drugs before the secondary patents expire. Xspray's goal is to become the leader in the development of improved drugs of PKIs already marketed for the treatment of cancer, which numbered to 72 in the end of 2021.

The company has patented manufacturing technology, equipment, and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). www.xspraypharma.com

This information is information that Xspray Pharma AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2022- 10-31 13:30 CET.

Attachments

Number of shares and votes in Xspray Pharma